Abstract:Background and aim: Human immunodeficiency virus (HIV) remains a significant global health challenge, with approximately 39 million people living with HIV worldwide as of 2022. Despite progress in antiretroviral therapy, achieving the UNAIDS "95-95-95" target to end the HIV epidemic by 2025 faces challenges, particularly in sub-Saharan Africa. The pursuit of an HIV vaccine is crucial, offering durable immunity and the potential to end the epidemic. Challenges in vaccine development include the lack of known immune correlates, suitable animal models, and HIV's high mutation rate. This study aims to explore the current state of HIV vaccine development, focusing on the challenges and innovative approaches being investigated. Methods: In writing this review, we conducted a search of medical databases such as PubMed, ResearchGate, Web of Science, Google Scholar, and Scopus. The exploration of messenger ribonucleic acid vaccines, which have proven successful in the SARS-CoV-2 pandemic, presents a promising avenue for HIV vaccine development. Understanding HIV-1's ability to infiltrate various bodily compartments, establish reservoirs, and manipulate immune responses is critical. Robust cytotoxic T lymphocytes and broadly neutralizing antibodies are identified as key components, though their production faces challenges. Innovative approaches, including computational learning and advanced drug delivery systems, are being investigated to effectively activate the immune system. Results and conclusions: Discrepancies between animal models and human responses have hindered the progress of vaccine development. Despite these challenges, ongoing research is focused on overcoming these obstacles through advanced methodologies and technologies. Addressing the challenges in HIV vaccine development is paramount to realizing an effective HIV-1 vaccine and achieving the goal of ending the epidemic. The integration of innovative approaches and a deeper understanding of HIV-1's mechanisms are essential steps toward this transformative breakthrough.

Biotech's role in advancing HIV vaccine development

HIV Vaccine Development at a Crossroads: New B and T Cell Approaches

Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects

HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence

Scientific Challenge and Advances of the HIV Vaccine Research

Progress in HIV-1 Vaccine Development.

Bending the Curve Through Innovations to Overcome Persistent Obstacles in HIV Prevention and Treatment

Moving candidate vaccines into development from research: lessons from HIV

HIV vaccine development and evaluation: realistic expectations

Clinical trials and recent progress in HIV vaccine development

Role of nanotechnology in HIV/AIDS vaccine development.

HIV Vaccination, is Breakthrough Underway?

HIV/AIDS vaccine development: are we walking out from the dark?

HIV Vaccines and Cure

HIV Vaccine for Prevention and Cure, A Mission Possible.

HIV Vaccine-Challenges and Opportunities

Technological challenges in the preclinical development of an HIV nanovaccine candidate

HIV Diagnostics and Vaccines: It Takes Two to Tango

Approaches to the Research in HIV Vaccine

Opportunities and challenges in new HIV therapeutic discovery: what is the next step?

Advanced Therapies for Human Immunodeficiency Virus